Which Wrаpаrоund principle mоst clоsely аligns with the System of Care value of coordinating multiple child‑serving systems?
Initiаl Pоst оn Dementiа Dementiа Dementia, оr “Major Neurocognitive Disorder” (as titled by DSM-5-TR) is not a disease but rather an umbrella term for significant cognitive decline in one or more cognitive areas, including language, memory, function, attention and visuospatial abilities. This decline is severe enough to interfere with independence in everyday activities and shows a distinct change from a previous level of functioning ability. Individuals with dementia may have difficulty remembering recent events, managing medications or finances, navigating familiar environments, communicating clearly, or regulating behavior and emotions. According to the World Health Organization (Greenblat, 2025), there were around 57 million people worldwide with dementia in 2021, with nearly 10 million new cases every year. The CDC (Kramarow & Tejada-Vera, 2022) recorded 288,436 dementia-related deaths among 65+ adults in the United States in 2022. As these numbers show, this is a very prevalent issue in healthcare worldwide and is only expected to increase as life expectancy continues to expand. Dementia, as mentioned previously, is an umbrella term for multiple causes of cognitive decline. There are four primary types: Alzheimer's disease, Vascular dementia, Lewy body dementia, and Frontal temporal lobe dementia. Alzheimer’s disease (AD) is the most common form of dementia in older adults. On an MRI, it is often shown as cerebral atrophy in the hippocampus and temporal lobes. It is caused by beta-amyloid plaques in the brain that disrupt communication between the cells. AD progresses fairly slowly, over months and years, and symptoms usually include orientation problems, language issues, and functioning issues. (Hens-Wijnen, 2023) While less common than AD, Frontal temporal lobe dementia (FTLD) is one of the leading causes of early-onset dementia (before age 65). Often seen as progressive behavior and language decline, it involves both the frontal and temporal lobes. Like AD, FTLD appears on MRI as atrophy, but is differentiated from AD by patterns quite accurately. (Urso et al., 2025) Vascular cognitive impairment (VCI) is the most common cause of significant cognitive decline, second only to AD. In VCI, the cognitive decline is often seen as a gradual or “stepwise” progression that affects function, attention, and processing speed. It is attributed to vascular pathologies, including but not limited to: hemorrhages, microblees, microinfarcts. In simple terms, it is damage to the brain cells caused by inconsistency or lack of blood flow. It can lead to long-term disability and is often treated by trying to manage the risk of stroke. (Jiménez‑Ruiz et al., 2024) Finally, Lewy body dementia (LBD), which is often presented as recurrent hallucinations, fluctuating cognition and random features of Parkinsonism. It is closely related to AD and Parkinson’s disease. Lewy bodies are bodies of the protein α‑synuclein that build up in a cell, causing it to lose communication with other cells and eventually die. (Sekiya et al., 2025) suggest that α‑synuclein agitation is likely the primary cause of neurodegeneration in LBD. The next consideration is whether dementia is influenced by genetics. In his paper, Bakulski et al. (2021) reviewed key genetic risk factors involved in AD development. While there are multiple contributing gene factors (APOE ε4 being one of the largest known and biggest risks), it takes more than just one in most cases. The genetic side of dementia is complicated, and the risks are rarely connected to only one gene. While we do see Familial Dementia (dementia cases that tend to run in families and are often seen as early-onset), which seems to show at least a genetic predisposition, we don’t yet fully understand what role genetics plays in dementia. The most common case, however, is Sporadic Dementia, which is seen without a clear family history and typically late-onset. Let’s take a deeper look into the manifestations of AD, since it is the most common form of dementia. Safiri et at. (2024) described the progression of Alzheimer’s disease from early memory impairment to severe cognitive and functional decline. Early-stage AD often looks like episodes of short-term memory loss, forgetting locations, conversations or appointments, repeating the same questions, and often misplacing items. We also see some functional challenges with planning and decision making, and often a decreased vocabulary or trouble finding words. The moderate stage presents a worsening of the same symptoms, along with greater difficulty with daily living activities such as handling finances, and driving. Patients also tend to have mood changes like irritability, depression or anxiety, and sometimes sleep disturbances. The late or severe stage of AD often looks really hard, with extreme decline in cognitive processing as well as a more physical decline. This looks like inappropriate behavior, loss of bladder or bowel control, bedridden status, and often a return to primitive reflexes such as gasping or sucking. The cause of death is often attributed to complications such as infection, malnutrition, and systemic illness. Dementia evaluation often has four components: Comprehensive Health History, Neurological Examination, Cognitive Screening Tools, and Functional Assessment. Atri et al. (2025) provide a clinical practical guideline for this evaluation. Comprehensive Health History takes a look at things like timeline, symptoms, other medical conditions, and family history to establish onset, progression, and possible cause. Next, a Neurological Examination looks to identify focal deficits or motor signs that suggest specific etiologies. It assesses cranial nerves, gait and balance, motor strength and Parkinsonian features. Then, Cognitive Screening Tools such as MMSE and MoCA test function, orientation, recall, language and skills. These are widely used, but they are limited, and are best at detecting subtle impairment. Finally there is Functional Assessment, which evaluates Instrumental ADLS (finances, medication, cooking, driving) and Basic ADLS (dressing, bathing, feeding, etc.) to determine whether or not cognitive impairment affects daily independence. All of these aspects of evaluation are taken into consideration in order to give timely, detailed and accurate diagnoses so that we can take steps towards slowing the progression of cognitive decline and improving the quality of life for our patients. In conclusion, dementia represents a complex group of neurocognitive disorders resulting from pathological processes within the brain. While AD remains the most common cause, other forms such as VD, LBD, and FTLD contribute significantly to the overall issue of cognitive decline. Understanding the distinct mechanisms, clinical manifestations, and progression patterns is critical for accurate diagnosis and effective management. As the global prevalence of dementia continues to rise, a solid foundation in pathophysiology and clinical presentation is essential for improving patient outcomes, supporting families, and guiding future healthcare practice. References Atri A, Dickerson BC, Clevenger C, et al. Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care. Alzheimer's Dement. 2025; 21: 1–32. https://doi.org/10.1002/alz.14333Links to an external site. Bakulski KM;Vadari HS;Faul JD;Heeringa SG;Kardia SLR;Langa KM;Smith JA;Manly JJ;Mitchell CM;Benke KS;Ware EB; (2021). Cumulative genetic risk and APOE ε4 are independently associated with dementia status in a multiethnic, population-based cohort. PubMed. https://pubmed.ncbi.nlm.nih.gov/33688582/ Greenblat, C. (2025, March 31). Dementia. World Health Organization. https://www.who.int/en/news-room/fact-sheets/detail/dementia HENSENS-WIJNEN, C. (2023). Dementia (P70). In H. Luijks, F. van de Laar, & H. Schers (Eds.), Morbidity in primary care: Epidemiologic data from Family Medicine Network (pp. 57–60). Radboud University Press. http://www.jstor.org/stable/jj.8784621.16 Jiménez-Ruiz, A., Aguilar-Fuentes, V., Becerra-Aguiar, N. N., Roque-Sanchez, I., & Ruiz-Sandoval, ose L. (2024). Vascular Cognitive Impairment and Dementia: a narrative review. SciFlo Brazil. https://www.scielo.br/j/dn/a/y64k3wNPtmwNRf5JrZcWv5C/?lang=enLinks to an external site. Kramarow, E. A., & Tejada-Vera, B. (2024, November 13). Dementia mortality in adults age 65 and older: United States, 2018–2022. Centers for Disease Control and Prevention. https://www.cdc.gov/nchs/data/hestat/dementia/dementia-mortality-adults-age-65.htm Safiri, S., Jolfayi, A. G., Fazlollahi, A., Morsali, S., Sarkesh, A., Sorkhabi, A. D., Golabi, B., Aletaha, R., Asghari, K. M., Hamidi, S., Mousavi, S. E., Jamalkhani, S., Karamzad, N., Sekiya, H., Matsubara, T., DeTure, M. A., & Dickson, D. W. (2025, November 3). Neuropathology of Lewy Body Dementia: Lewy-related pathology, α-synuclein oligomers, and comorbid pathologies - molecular neurodegeneration. SpringerLink. https://link.springer.com/article/10.1186/s13024-025-00900-6 Shamekh, A., Mohammadinasab, R., Sullman, M. J. M., Şahin, F., & Kolahi, A.-A. (2024, December 15). Alzheimer’s disease: A comprehensive review of epidemiology, risk factors, symptoms, diagnosis, management, caregiving, advanced treatments, and associated challenges. Frontiers. https://doi.org/10.3389/fmed.2024.1474043Links to an external site. Urso, D., Giannoni-Luza, S., Brayne, C., Ray, N., & Logroscino, G. (2025, November 1). Incidence and prevalence of frontotemporal dementia: A systematic review and meta-analysis. JAMA Neurology. https://pmc.ncbi.nlm.nih.gov/articles/PMC12418226/
Which оf the fоllоwing is not а requirement for clаiming the credit for child аnd dependent care expenses?